Childhood Cancer Survivor Study
BioPathology Processes
Sue Hammond MD
Nationwide Children’s Hospital, Columbus, Ohio

I. Confirmation of self-reported second malignancies

II. Receive, process, and store paraffin material

III. Provide paraffin material to investigators with approved projects
CCSS Confirmation of SMNs

- Majority of second malignancies are self-reported
- These reports are first screened by Joe Neglia
- Pathology reports are pursued for likely SMNs
- Pathology reports are reviewed and categorized by Sue Hammond (in original cohort ~ 50% confirmed)
- A final review is performed by Joe Neglia
- For a minority of cases, a second condition is confirmed by either other medical records or the National Death Index
Re –request of SMN material from original cohort, Spring 2015
Limited to breast and thyroid cancers.
Institutions much more likely to charge for materials than previously.

SPRING 2015 PILOT
Pilot
N=42
(38 participants)

20 (48%) Block to return
14 (33%) Block to keep
6 (15%) Unstained slides
2 (5%) H&E slides only
# Childhood Cancer Survivor Study

**Paraffin Tissue Archive**  May 2015

<table>
<thead>
<tr>
<th>SMN diagnosis</th>
<th>N</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer</td>
<td>71</td>
<td>Other CA 14</td>
</tr>
<tr>
<td>Thyroid cancer</td>
<td>46</td>
<td>Melanoma 9</td>
</tr>
<tr>
<td>Meningiomas</td>
<td>39</td>
<td>Lymphoma/ 14</td>
</tr>
<tr>
<td>Sarcomas</td>
<td>23</td>
<td>Leukemia</td>
</tr>
<tr>
<td>Malignant CNS</td>
<td>19</td>
<td>NMSC 5</td>
</tr>
<tr>
<td>AdenoCA</td>
<td>12</td>
<td>other/unk 6</td>
</tr>
</tbody>
</table>
Upcoming CCSS Pathology Changes

• Michael Arnold MD PhD  
  Pediatric Pathologist, Nationwide Children’s  
  – will oversee SMN pathology review and  
  – CCSS Paraffin Tissue Archive

• Proposal in development for Logistics of CCSS Paraffin Archive to be done by the BioPathology Center at Nationwide Children’s

• Nilsa C. Ramirez MD, Director